Score Your Stock

US stock · figures in US dollars · scored on full-year results

Agilent Technologies Agilent Technologies, Inc. Common Stock

A · Healthcare · Diagnostics & Research
Top 40% of scored stocks
OkayTop 40% of scored stocks
Weak Spot

Agilent Technologies scores 57/100 on fundamentals: in the top 40% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (83/100); its weakest is Price Fairness (0/100). It carries 1 warning flag: Weak Spot.

Best
Financial 83
Weakest
Price 0
  • Carries a Weak Spot flag

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 49.3b#234 of 503 in the S&P 500EPSUS$ 5.07P/E34.2×✗ vs sector median 29.6×P/B6.7×✗ vs sector median 3.7×Div yield1%Bottom 29% in the S&P 50052w range · 89% of range108.35182.99
as of 31 Oct 2026

Nearby peers

Ranks #22 of 60 in Healthcare by score

#1Universal Health Services79#20Idexx Laboratories61#21McKesson59
#22Agilent Technologies57
#23Edwards Lifesciences57#24Zoetis57

One-Minute Summary

Why Agilent Technologies scores 57

A financially strong, expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

80
Why 80?
Pillar score: (2 + 1 + 1 + 2 + 2) = 8 of 10 points → 80
Return on Equity (ROE)20%Strong4-Year Revenue Growth+3%/yrOkay4-Year Profit Growth+5%/yrOkayNet Profit Margin20%StrongQuarterly Momentum+9%Strong
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↑ +16.1%Equity ↑ +26%ROE % 19.6%
Net ProfitEquityROE %
1.2b1.3b1.3b1.4b5.8b5.9b6.7b7.4b202320242025TTM21.2%21.9%19.3%19.6%

Revenue & Net Profit, with Net Margin

Revenue ↑ +7.9%Net Profit ↑ +16.1%Net Margin % 19.5%
RevenueNet ProfitNet Margin %
6.8b6.5b6.9b7.4b1.2b1.3b1.3b1.4b202320242025TTM18.1%19.8%18.8%19.5%

Sales have been roughly flat for 4 years: the business isn't really growing, just maintaining.

Profit climbed about 16.1% over 4 years: the business keeps more money as it grows.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +10.4%Net Profit ↑ +3.1%Net Margin % 19.3%
RevenueNet ProfitNet Margin %
1.7b1.7b1.7b1.7b1.9b1.8b1.8b1.9b351m318m215m336m434m305m339m362mQ4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26Q3'2620.6%18.9%12.9%19.3%23.3%17%18.5%19.3%
▼▼▼▲▲▬▲▲

Sales grew about 10.4% over the last 8 quarters: customers keep spending more with this company.

Profit has moved sideways over the last 8 quarters.

Why 83?
Pillar score: (1 + 2 + 2) = 5 of 6 points → 83
Debt-to-Equity0.5×OkayCurrent Ratio2.1×StrongInterest Coverage16.6×Strong
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↑ +44.4%Equity ↑ +26%D/E 0.5×
Total DebtEquityD/E
2.7b3.4b3.4b3.9b5.8b5.9b6.7b7.4b202320242025TTM0.5×0.6×0.5×0.5×

Borrowings grew about 44.4% over 4 years: watch this; rising debt adds pressure in bad times.

Short-term assets vs bills, with Current Ratio

Current Assets ↑ +12.1%Current Liabilities ↑ +42.8%Current Ratio 2.1×
Current AssetsCurrent LiabilitiesCurrent Ratio
4.2b4.0b4.6b4.7b1.6b1.9b2.3b2.3b202320242025TTM2.6×2.1×2×2.1×
Why 63?
Pillar score: (0 + 1 + 2 + 2) = 5 of 8 points → 63
Dividend Quality1%Weak
Payout ratio: 20%
Operating Cash FlowPositive but bumpyOkayFree Cash FlowPositive & growingStrongCash & Cash EquivalentsGrowing & covers near-term debtStrong
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↓ -9.2%Free CF ↓ -14%
Operating CFFree CF
1.8b1.8b1.6b1.6b1.5b1.4b1.2b1.3b202320242025TTM

Cash keeps coming in, though unevenly: fine, but worth keeping an eye on.

Cash vs Total Debt

Cash ↑ +10.6%Total Debt ↑ +44.4%
CashTotal Debt
1.6b1.3b1.8b1.8b2.7b3.4b3.4b3.9b202320242025TTM

Dividends per Share, with Yield

DPS (cents) ↓ -9.3%Yield % 0.6%
DPS (cents)Yield %
22.522.522.523.623.623.624.824.825.525.5112.511899.2102202320242025TTM0.9%0.9%0.8%0.6%

Dividends were cut during this period: payouts here are not guaranteed pocket money.

Why 0?
Pillar score: (0 + 0 + 0) = 0 of 6 points → 0
P/E Ratio34.2×WeakP/B Ratio6.7×WeakPEG Ratio6.7Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 174.87US$ 142.24US$ 109.61Oct '25Feb '26Jun '26Oct '26

The share price is up about 20.4% over the past year.

Why 58?
Pillar score: (2 + 0 + 2 + 1 + 0 + 2) = 7 of 12 points → 58
Earnings ConsistencySteadyStrongDebt Trend (4yr)RisingWeakShare Count Trend (4yr)-1%/yrStrongInventory vs Sales (4yr)+0.1 pp/yr vs salesOkayAsset Turnover Trend (4yr)-16.9%WeakQuarterly Consistency1 of 4 quarters downStrong
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +7.9%Inventory ↑ +8.3%Inv. % of Rev. 15.2%
RevenueInventoryInv. % of Rev.
6.8b6.5b6.9b7.4b1.0b972m1.0b1.1b202320242025TTM15.1%14.9%14.8%15.2%
Ranks #22 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#20Idexx Laboratories61#21McKesson59
#22Agilent Technologies (you)57
#23Edwards Lifesciences57#24Zoetis57

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDividend Payout RatioDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 7.4bUS$ 1.4bUS$ 1.6bUS$ 1.3bUS$ -342.0mUS$ 1.8bUS$ 3.9bUS$ 304.0mUS$ 7.4bUS$ 4.7bUS$ 2.3bUS$ 14.0bUS$ 6.6bUS$ 1.1bUS$ 102.0m20%20%0.5×2.1×16.6×20%----
2025US$ 6.9bUS$ 1.3bUS$ 1.6bUS$ 1.2bUS$ -407.0mUS$ 1.8bUS$ 3.4bUS$ 304.0mUS$ 6.7bUS$ 4.6bUS$ 2.3bUS$ 12.7bUS$ 6.0bUS$ 1.0bUS$ 99.2m19%19%0.5×2.0×13.8×22%1%31.6×6.1×24.5
2024US$ 6.5bUS$ 1.3bUS$ 1.8bUS$ 1.4bUS$ -378.0mUS$ 1.3bUS$ 3.4bUS$ 45.0mUS$ 5.9bUS$ 4.0bUS$ 1.9bUS$ 11.8bUS$ 5.9bUS$ 972.0mUS$ 118.0m22%20%0.6×2.1×16.8×21%1%29.8×6.5×14.0
2023US$ 6.8bUS$ 1.2bUS$ 1.8bUS$ 1.5bUS$ -298.0mUS$ 1.6bUS$ 2.7b-US$ 5.8bUS$ 4.2bUS$ 1.6bUS$ 10.8bUS$ 4.9bUS$ 1.0bUS$ 112.5m21%18%0.5×2.6×15.1×21%1%25.1×5.3×1.3